You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥(01093.HK)升幅擴至12%交投活躍 以1.7億人幣奪中重度哮喘產品獨家開發權
阿思達克 03-11 14:59
石藥集團(01093.HK)繼昨天一舉升破20天、10天及牛熊線(8.66元)後,今天股價進一步逼近五個月高位,午後高見9.8元,現造9.74元,續漲12%,為最強藍籌,成交進一步增至2.34億股,為近期罕見,涉資22.19億元。

石藥繼昨天公布簽訂腫瘤產品授權商業化協議後,今天又與康諾亞生物訂立協議,以總代價1.7億人民幣取得中重度哮喘和慢性阻塞性肺病等呼吸系統疾病產品獨家開發權,以在內地進行開發與商業化,並成為上市許可持有人。

中金發表研究報告指,石藥集團獲上海倍而達藥業BPI-7711膠囊(三代EGFR)在國內的獨家產品授權和商業化權利,並得到BPI-1178膠囊商業化授權優先談判權,預期將進一步加強腫瘤創新管線。該行預期隨著一線適應症納入醫保及更多國產產品上市,國內三代EGFR藥物有望取代一、二代EGFR藥物,市場容量達到逾百億元人民幣。維持「跑贏行業」評級,目標價升至12元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account